Showing results (11-20 of 540) with videos related to

Sort By:
Pageof 54
Biomed Research International|October 31, 2017
Molecular Mechanisms and Treatment Strategies in Diabetic Nephropathy: New Avenues for Calcium Dobesilate-Free Radical Scavenger and Growth Factor InhibitionHermann Haller, Linong Ji, Klaus Stahl, et al.
Plos Medicine|December 10, 2019
Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysisJan Menne, Eva Dumann, Hermann Haller, et al.
Journal of the American Heart Association|April 30, 2014
The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) observational follow-up study: benefits of RAS blockade with olmesartan treatment are sustained after study discontinuationJan Menne, Eberhard Ritz, Luis M Ruilope, et al.
Transplantation|April 26, 2005
Kidney graft function determines endothelial progenitor cell number in renal transplant recipientsKirsten de Groot, Ferdinand H Bahlmann, Elisabeth Bahlmann, et al.
Journal of Hypertension|October 3, 2014
Prevention of electrocardiographic left ventricular remodeling by the angiotensin receptor blocker olmesartan in patients with type 2 diabetesUlrike Raff, Christian Ott, Luis M Ruilope, et al.
Blood Pressure|April 14, 2020
Influence of pre-treatment blood pressure levels on antihypertensive drug benefits in diabetics: the roadmap experienceChristos Chatzikyrkou, Florian G Scurt, Jan Menne, et al.
BMC Nephrology|July 16, 2013
Zinc-alpha2-glycoprotein in patients with acute and chronic kidney diseaseInga Sörensen-Zender, Jan Beneke, Bernhard M W Schmidt, et al.
Plos One|December 16, 2020
Correction: Calcium dobesilate reduces VEGF signaling by interfering with heparan sulfate binding site and protects from vascular complications in diabetic miceFlorence Njau, Nelli Shushakova, Heiko Schenk, et al.
Plos One|January 15, 2020
Calcium dobesilate reduces VEGF signaling by interfering with heparan sulfate binding site and protects from vascular complications in diabetic miceFlorence Njau, Nelli Shushakova, Heiko Schenk, et al.
Journal of Hypertension|August 14, 2008
Valsartan in combination with lisinopril versus the respective high dose monotherapies in hypertensive patients with microalbuminuria: the VALERIA trialJan Menne, Csaba Farsang, László Deák, et al.
Pageof 54